Prospective Study of White Blood Cells
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: White blood cell and blood collection.
- Who it may be relevant to
- Registry conditions: Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
Overview
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
Interventions
- Other White blood cell and blood collection
Mononucleocytes will be collected via apheresis
Primary outcome measures
- WBC characterisation to support the development of engineered regulatory T cells. [Time frame: 5 years]
Eligibility criteria
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-only
Study locations
United Kingdom · 1 center
- Quell Investigator Site 01 — London
Identifiers
NCT: NCT04838171 · QEL-RP-001